Home  /  Resource Library  /  893MO An open-label, single-center, phase II, single-arm trial of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma

893MO An open-label, single-center, phase II, single-arm trial of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma

ESMO 2020: Results of a phase II study examining camrelizumab combined with apatinib for treatment of relapsed peripheral t-cell lymphomas.